Member Company

Mila

Mila develops digital therapeutics for children with neurodevelopmental disorders.

Mila-Learn is designed for early treatment and to increase therapeutic continuity for children with specific learning disorders (SLD). Mila-Learn has been evaluated through 3 clinical and usabilities studies involving 6000 french children and showed a strong adherence to therapy – 3.5 sessions on average per week and per child – thanks a unique experience brought by music labels partners. Mila-Learn is currently in pivotal phase and is aiming for FDA clearance and CE Mark by the end of 2022.

Copyright © 2021 Digital Therapeutics Alliance™